$EHC

Price Andrew L sold $630K of EHC

Price Andrew L (Chief Accounting Officer) sold 5,211 shares of Encompass Health Corp (EHC) at $120.93 ($0.63M total) on 2026-08-31.

Original reporting
SEC EDGAR · Price Andrew L
Published Sep 1, 2026, 4:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EHC
Bearish
medium confidence
Mentioned
$EHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EHCBearishLow
01

Why it matters

A mid‑size insider sale can be interpreted as a negative signal, but without further context its impact is limited.

02

Market read

The filing is a routine disclosure; traders may watch for any price reaction but overall market relevance is low.

03

What to watch

Potential tax planning or diversification; no change in operational fundamentals.

Relevance 5/10Novelty 4/10Timing: filing date 2026-09-01, reflects sale on 2026-08-31

Background

Form 4 filing discloses insider transactions to the SEC, providing transparent ownership changes.

Company-level read

Ticker impact

$EHCBearishMedium confidence
Context

Chief Accounting Officer sold 5,211 shares for $630K, reducing his stake to 69,483 shares.

Expected impact

Possible modest downward pressure over the next few days.

Evidence & confidence

Sale size is moderate for a mid‑cap; insider is a senior officer, but no accompanying news suggests a larger catalyst.

Market effects

Minimal impact on healthcare services sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be unrelated to company outlook; may not affect price.

Key entities

  • Encompass Health Corp

    Provider of post‑acute healthcare services.

  • Price Andrew L

    Chief Accounting Officer of Encompass Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EHCHighAI 8/10

Encompass Health (EHC): This Rehab Hospital Giant Just Raised Its Own Bar Again

Encompass Health (EHC) reported Q2 revenue of $1.597B, up 9.6%, and adjusted EPS of $1.55, up 10.7%. The company raised full-year guidance for revenue, EBITDA, and EPS. It also increased its stock repurchase authorization to $1B. Patient volume and revenue per discharge grew, but free cash flow fell due to higher capital spending. Long-term debt rose to $2.598B.

$EHCMedAI 8/10

Does Stronger EPS, Higher 2026 Targets, and Bigger Buybacks Change The Bull Case For Encompass Health (EHC)?

Encompass Health (EHC) reported adjusted EPS of $1.55, raised its 2026 outlook, and increased its share buyback program to $1B. The company plans to open new hospitals and add beds, signaling confidence in long-term demand. Analysts project $7.9B revenue and $806.1M earnings by 2029, a 22% upside from current prices. Labor shortages remain a key risk.

$EHCMedAI 8/10

Encompass Health (EHC) Q2 2026 Earnings Call Transcript

Encompass Health (EHC) reported Q2 2026 net operating revenue of $1.597B (+9.6% YoY), adjusted EBITDA of $348M (+9.2%), and adjusted EPS of $1.55 (+10.7%). Full-year 2026 guidance was raised: revenue $6.41B-$6.49B, adjusted EBITDA $1.365B-$1.395B, adjusted EPS $6.02-$6.25. The company also increased its $1B share repurchase authorization.

$EHCMed

Encompass Health Named Top SMidCap Pick by TD Cowen

TD Cowen analyst Ryan Langston reiterated Encompass Health (EHC) as a top small- and mid-cap pick after its strong Q2 FY2026 results. Adjusted EBITDA was $348M (+3% vs consensus), revenue $1.597B (+10%), and EPS $1.55. Same-store volume rose 2.8%. EHC raised FY2026 adjusted EBITDA guidance by $15M and authorized a $1B share repurchase.